Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10780626 | 0.83 | SRD5A1 (0.41) | ADRA1ATSHRRIPK1SRD5A1ROCK1 | |
| SCHEMBL5791958 | 0.83 | HRH1 (0.38) | HPGDADRA1AADRA1DADRA2ATSHR | |
| SCHEMBL1982809 | 0.80 | SMN1; SMN2 (0.42) | TSHRRIPK1SRD5A1NOTUMROCK1 | |
| SCHEMBL8032869 | 0.79 | AVPR1A (0.41) | ADRA1AADRA2ATSHRRIPK1MAPK1 | |
| SCHEMBL8138134 | 0.75 | ATAD2 (0.33) | HPGDSMN1; SMN2 | |
| SCHEMBL4267398 | 0.75 | RNASEH1 (0.45) | HPGD | |
| SCHEMBL16207990 | 0.73 | TSHR (0.38) | TSHRRIPK1NOTUM | |
| SCHEMBL432928 | 0.73 | GRM5 (0.43) | HPGDRIPK1HTR1AGABRA1SLC6A4 | |
| SCHEMBL10953852 | 0.72 | NPC1 (0.46) | MAPK1 | |
| SCHEMBL14511561 | 0.70 | BRPF1 (0.42) | HPGDADRA1AADRA1DADRA2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | claimed |
| US-9806270-B2 | 4H-imidazo[1,2-a]imidazoles for electronic applications | UDC IRELAND LIMITED (IE) | 2017-10-31 | — | — | US | disclosed |
| US-9502664-B2 | 4H-imidazo[1,2-a]imidazoles for electronic applications | UDC IRELAND LIMITED (IE) | 2016-11-22 | — | — | US | disclosed |
| US-20160190480-A1 | 4H-Imidazo[1,2-a]imidazoles for Electronic Applications | BASF SE (DE) | 2016-06-30 | — | — | US | disclosed |
| US-20140252280-A1 | 4H-IMIDAZO[1,2-A]IMIDAZOLES FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20120241681-A1 | 4H-Imidazo[1,2-a]imidazoles for Electronic Applications | BASF SE (DE) | 2012-09-27 | — | — | US | disclosed |
| US-7608717-B2 | Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-10-08 | — | — | US | disclosed |
| US-7585873-B2 | antiserotonine agents; central nervous system disorders; Alzheimer's disease; 3-(Phenylthio)-1H-pyrrolo[2,3-b]pyridine | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2001081350-A1 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2001-11-01 | — | — | WO | disclosed |
| EP-1121358-A1 | HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS | AstraZeneca AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001040222-A1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1082323-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca UK Limited (GB) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082322-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| EP-1007525-A1 | AMINOMETYL OXOOXAZOLIDINYL BENZENE DERIVATIVES | ZENECA LIMITED (GB) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000021960-A1 | HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999064417-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064416-A2 | OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999011642-A1 | AMINOMETYL OXOOXAZOLIDINYL BENZENE DERIVATIVES | ZENECA LIMITED (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120241681-A1 | 4H-Imidazo[1,2-a]imidazoles for Electronic Applications | EIF4A1, ITPR2, ITPR1 | HPGD 1129/4885ADRA1A 655/4885ADRA1D 1622/4885 |
| US-20090253711-A1 | HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR2C, HTR3B | HPGD 692/4885ADRA1A 238/4885ADRA1D 232/4885 |
| US-20030144263-A1 | Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them | CYP3A5, CYP2D6, OXA1L | HPGD 965/4885ADRA1A 3499/4885ADRA1D 2228/4885 |
| US-20160190480-A1 | 4H-Imidazo[1,2-a]imidazoles for Electronic Applications | PAH, NISCH, KCNH1 | HPGD 486/4885ADRA1A 905/4885ADRA1D 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.